Impact of the Inflation Reduction Act on Drug Pricing

This chapter explores the transformative changes brought by the Inflation Reduction Act, particularly Medicare's newfound ability to negotiate drug prices, resulting in considerable savings for seniors. It highlights the advocacy efforts, challenges, and contentious debates involving pharmaceutical companies opposing these reforms. Additionally, the chapter discusses the media’s portrayal of these issues and the Biden administration’s struggle to communicate its policy achievements effectively.